NEJM Group, publisher of the New England Journal of Medicine, today announced the launch of its newest title, NEJM AI, a peer-reviewed, monthly journal dedicated to the latest research and application of artificial intelligence (AI) and machine learning in medicine. In addition to original research articles, the journal publishes reviews, policy perspectives and educational material for clinicians, scientists, health care leaders, policy makers, regulators, and executives with pharmaceutical, device-manufacturing and technology companies.

Salus Optima, a leading provider in AI-enabled digital health and wellness solutions, and the Consumer Health division of Bayer have launched a strategic partnership to empower people on their healthy aging journey. The partnership elevates the shared aspiration of both companies to transform self-care by offering precision health solutions to enable consumers to better understand and make informed decisions about their own personal health and lifestyle choices.

Ebenbuild, a company developing personalized, AI-driven virtual lungs to support clinical decisions and digital clinical trials, announced its participation in the research project Personalized Lung Twins for the Treatment of Acute Respiratory Distress Syndrome (UBIC) in collaboration with the University Hospital Schleswig-Holstein, Augsburg University Hospital, University Hospital Carl Gustav Carus Dresden, University Hospital RWTH Aachen and University Medical Center Mannheim.

The European start-up HealthSage AI announces the launch of its Open Source Generative AI Platform fully dedicated to healthcare: a trusted and transparent foundation for the development of AI applications for healthcare.

The first release of HealthSage AI's Large Language Model, Note-to-FHIR, transforms clinical notes and other types of unstructured text into a structured FHIR output.

Bayer continues to advance its comprehensive Radiology portfolio with progress in the development pipeline of its investigational contrast agent as well as new innovations in the area of Artificial Intelligence (AI).

The NHS exists to serve patients. But more could be done to make their experience a key focus when it comes to technology adoption, senior NHS delegates told a recent roundtable. SPARK TSL reports.

Sustained challenges faced by clinical teams on the frontline of an NHS under pressure are well documented in daily headlines.

World leading AI pioneer, Orbital Global, is proud to announce that it is a member of a new Horizon Europe research and innovation consortium, which aims to personalise prevention and treatment of cardiovascular diseases. Led by Novo Nordisk and Maastricht University, the iCARE4CVD (individualised care from early risk of cardiovascular disease to established heart failure) consortium is formed of thirty-three leading international partners from civil society, academia, and industry.